HRMY HARMONY BIOSCIENCES HOLDINGS INC Other Situations 8-K Filing 2023 - Phase 3 INTUNE study on pitolisant accelerated Harmony Biosciences Holdings, Inc. has accelerated the timeline for completing its Phase 3 INTUNE study on pitolisant, with enrollment expected to be completed in Q2 2023 and topline data anticipated in Q4 2023.Get access to all SEC 8-K filings of the HARMONY BIOSCIENCES HOLDINGS INC